卡奇霉素
单克隆抗体
神经母细胞瘤
转移
医学
癌症研究
化疗
抗原
细胞毒性T细胞
抗体
免疫疗法
癌症
免疫学
生物
内科学
细胞培养
体外
生物化学
遗传学
作者
Holger N. Lode,R. Reisfeld,R. Handgretinger,K. C. Nicolaou,Gerhard Gaedicke,Wolfgang Wrasidlo
出处
期刊:PubMed
日期:1998-07-15
卷期号:58 (14): 2925-8
被引量:49
摘要
The suppression of metastases in malignant diseases is one of the major goals in targeted chemotherapy. This was achieved with an antibody drug conjugate between a novel, rationally designed enediyene antibiotic calicheamicin theta(I)1 of exceptionally high cytotoxic potency and an antiganglioside GD2 monoclonal antibody 14G2a. Effective suppression of hepatic metastases was demonstrated in a novel syngeneic model of murine neuroblastoma that simulates the situation in patients in terms of antigen heterogeneity and presence of the target antigen on normal tissues. Here, we describe the first successful use of calicheamicin theta(I)1 for targeted chemotherapy in a clinically relevant syngeneic metastasis model.
科研通智能强力驱动
Strongly Powered by AbleSci AI